



Toxicological Profile for 1,1,2-Trichloroethane

March 2021



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
March 2021	Final toxicological profile released
December 2019	Draft for public comment toxicological profile released
October 2010	Addendum to the toxicological profile released
December 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Jennifer Przybyla, Ph.D.

Julie M. Klotzbach, Ph.D.

Kelly Salinas, Ph.D.

Mario Citra, Ph.D.

Jenny S. Crisman, B.S.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice.

PEER REVIEWERS

1. Ivan Rusyn, M.D., Ph.D.; Professor and Chair; Department of Veterinary Integrative Biosciences; College of Vet Medicine & Biomedical Sciences; Texas A&M University; College Station, Texas
2. James V. Bruckner, Ph.D.; Professor Emeritus of Pharmacology & Toxicology; Department of Pharmaceutical & Biomedical Sciences; College of Pharmacy; University of Georgia; Athens, Georgia
3. David C. Dorman, DVM, Ph.D., DABVT, DABT; Professor of Toxicology; North Carolina State University; College of Veterinary Medicine; Department of Molecular Biomedical Sciences; Raleigh, North Carolina

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	1
1.3 MINIMAL RISK LEVELS (MRLs)	7
CHAPTER 2. HEALTH EFFECTS	10
2.1 INTRODUCTION	10
2.2 DEATH	31
2.3 BODY WEIGHT	32
2.4 RESPIRATORY	33
2.5 CARDIOVASCULAR	34
2.6 GASTROINTESTINAL	35
2.7 HEMATOLOGICAL	35
2.8 MUSCULOSKELETAL	36
2.9 HEPATIC	36
2.10 RENAL	38
2.11 DERMAL	40
2.12 OCULAR	40
2.13 ENDOCRINE	41
2.14 IMMUNOLOGICAL	41
2.15 NEUROLOGICAL	42
2.16 REPRODUCTIVE	44
2.17 DEVELOPMENTAL	45
2.18 OTHER NONCANCER	46
2.19 CANCER	46
2.20 GENOTOXICITY	47
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	51
3.1 TOXICOKINETICS	51
3.1.1 Absorption	51
3.1.2 Distribution	53
3.1.3 Metabolism	53
3.1.4 Excretion	55
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	55
3.1.6 Animal-to-Human Extrapolations	56
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	57
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	58
3.3.1 Biomarkers of Exposure	59
3.3.2 Biomarkers of Effect	59
3.4 INTERACTIONS WITH OTHER CHEMICALS	60

CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	62
4.1 CHEMICAL IDENTITY	62
4.2 PHYSICAL AND CHEMICAL PROPERTIES	62
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	64
5.1 OVERVIEW	64
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	66
5.2.1 Production	66
5.2.2 Import/Export	67
5.2.3 Use	67
5.2.4 Disposal	68
5.3 RELEASES TO THE ENVIRONMENT	68
5.3.1 Air	70
5.3.2 Water	71
5.3.3 Soil	72
5.4 ENVIRONMENTAL FATE	73
5.4.1 Transport and Partitioning	73
5.4.2 Transformation and Degradation	74
5.5 LEVELS IN THE ENVIRONMENT	76
5.5.1 Air	77
5.5.2 Water	79
5.5.3 Sediment and Soil	79
5.5.4 Other Media	80
5.6 GENERAL POPULATION EXPOSURE	80
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	82
CHAPTER 6. ADEQUACY OF THE DATABASE	84
6.1 Information on Health Effects	84
6.2 Identification of Data Needs	84
6.3 Ongoing Studies	90
CHAPTER 7. REGULATIONS AND GUIDELINES	91
CHAPTER 8. REFERENCES	93
APPENDICES	
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR 1,1,2-TRICHLOROETHANE	B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR 1,1,2-TRICHLOROETHANE	C-1
APPENDIX D. USER'S GUIDE	D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F. GLOSSARY	F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to 1,1,2-Trichloroethane	3
1-2. Health Effects Found in Animals Following Oral Exposure to 1,1,2-Trichloroethane	4
1-3. Summary of Sensitive Targets of 1,1,2-Trichloroethane – Inhalation.....	8
1-4. Summary of Sensitive Targets of 1,1,2-Trichloroethane – Oral.....	9
2-1. Overview of the Number of Studies Examining 1,1,2-Trichloroethane Health Effects	12
2-2. Levels of Significant Exposure to 1,1,2-Trichloroethane – Inhalation.....	16
2-3. Levels of Significant Exposure to 1,1,2-Trichloroethane – Oral.....	24
3-1. Proposed Metabolic Pathway of 1,1,2-Trichloroethane	54
5-1. Number of NPL Sites with 1,1,2-Trichloroethane Contamination	64
6-1. Summary of Existing Health Effects Studies on 1,1,2-Trichloroethane By Route and Endpoint	85

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 1,1,2-Trichloroethane	8
2-1. Levels of Significant Exposure to 1,1,2-Trichloroethane – Inhalation.....	13
2-2. Levels of Significant Exposure to 1,1,2-Trichloroethane – Oral.....	18
2-3. Levels of Significant Exposure to 1,1,2-Trichloroethane – Dermal	29
2-4. Genotoxicity of 1,1,2-Trichloroethane <i>In Vivo</i>	48
2-5. Genotoxicity of 1,1,2-Trichloroethane <i>In Vitro</i>	48
4-1. Chemical Identity of 1,1,2-Trichloroethane	62
4-2. Physical and Chemical Properties of 1,1,2-Trichloroethane	62
5-1. Facilities that Produce, Process, or Use 1,1,2-Trichloroethane	67
5-2. Estimated Emissions of 1,1,2-Trichloroethane.....	68
5-3. Releases to the Environment from Facilities that Produce, Process, or Use 1,1,2-Trichloroethane	70
5-4. Lowest Limit of Detection Based on Standards	76
5-5. Summary of Environmental Levels of 1,1,2-Trichloroethane.....	76
5-6. 1,1,2-Trichloroethane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	77
5-7. Summary of Annual Concentration of 1,1,2-Trichloroethane (ppbv) Measured in Ambient Air at Locations Across the United States	77
7-1. Regulations and Guidelines Applicable to 1,1,2-Trichloroethane.....	91